Citations

Mayo Clinic

Showing 10 of 108523 citations.

Operations research/management contributions to emergency department patient flow optimization: Review and research prospects
Austin, Garrett, Traub, Stephen J., Saghafian, Soroush

IIE Transactions on Healthcare Systems Engineering | June 11, 2015 | Volume: 5 | Issue: 2 | Pages: 101-123

10.1080/19488300.2015.1017676 Get It

Association between history of psychosis and cardiovascular disease in bipolar disorder
Prieto, Miguel L. , Sutor, Bruce, Kung, Simon , Cuéllar‐Barboza, Alfredo B. , Ösby, Urban, Chauhan, Mohit , Westman, Jeanette , Geske, Jennifer R. , Colby, Colin , Ryu, Euijung , Frye, Mark A. , Bobo, William V. , Colby, Colin L., McElroy, Susan L. , Hayes, Sharonne N. , Fuentes, Manuel Enrique , Crow, Scott J. , Biernacka, Joanna M. , Cuellar-Barboza, Alfredo , Geske, Jennifer , Chauhan, Mohit

Bipolar Disorders | June 11, 2015 | Volume: 17 | Issue: 5 | Pages: 518-527

10.1111/bdi.12302 | PMID 26062406 Get It

ObjectivesTo determine whether clinical features of bipolar disorder, such as history of psychosis, and cardiovascular disease (CVD) risk factors contribute to a higher risk of CVD among patients with bipolar disorder.MethodsThis cross‐sectional study included a sample of 988 patients with bipolar I or bipolar II disorder or schizoaffective bipolar type confirmed by the Structured Clinical Interview for DSM‐IV‐TR disorders (SCID). Medical comorbidity burden was quantified utilizing the Cumulative Illness Severity Rating Scale (CIRS). This 13‐item organ‐based scale includes cardiac disease severity quantification. Confirmed by medical record review, patients who scored 1 (current mild or past significant problem) or higher in the cardiac item were compared by logistic regression to patients who scored 0 (no impairment), adjusting for CVD risk factors that were selected using a backwards stepwise approach or were obtained from the literature.ResultsIn a multivariate model, age [odds ratio (OR) = 3.03, 95% confidence interval (CI): 1.66–5.54, p < 0.0001], hypertension (OR = 2.43, 95% CI: 1.69–3.55, p < 0.0001), and history of psychosis (OR = 1.48, 95% CI: 1.03–2.13, p = 0.03) were associated with CVD. When CVD risk factors from the literature were added to the analysis, age (OR = 3.19, 95% CI: 1.67–6.10, p = 0.0005) and hypertension (OR = 2.46, 95% CI: 1.61–3.76, p < 0.01) remained significant, with psychosis being at the trend level (OR = 1.43, 95% CI: 0.96–2.13, p = 0.08).ConclusionsThe phenotype of psychotic bipolar disorder may reflect higher illness severity with associated cardiac comorbidity. Further studies are encouraged to clarify the effect of the disease burden (i.e., depression), lifestyle, and treatment interventions (i.e., atypical antipsychotics) on this risk association.
Incidence of Melanoma in Children: A Population‐Based Study in Olmsted County, Minnesota
Lowe, Garrett C., Brewer, Jerry D., Peters, Margot S. , Davis, Dawn M. R., Davis, Dawn Marie R.

Pediatric Dermatology | June 10, 2015 | Volume: 32 | Issue: 5 | Pages: 618-620

10.1111/pde.12621 | PMID 26059893 Get It

AbstractBackgroundThe incidence of melanoma has been rising in the United States, with conflicting evidence regarding trends in children.MethodsWe identified patients 0 to 17 years old with a diagnosis of melanoma from January 1, 1970, through December 31, 2010, in Olmsted County, Minnesota. Information on survival and demographic characteristics was abstracted, and estimates of true incidence were calculated.ResultsThe estimated true incidence of melanoma in children from 1970 to 2010 was found to be 0.62 per 100,000 girls and 0.45 per 100,000 boys. The incidence of melanoma in this population did not increase with time after adjusting for age and sex. Only one case of metastatic disease (lymph node) was identified. Girls were more commonly affected and the mean age of disease onset was 14 years. Five of the seven melanomas in this population arose in association with a nevus, and none involved the trunk. Overall and disease‐specific survival rates were not calculated because all patients studied were alive at the last follow‐up.ConclusionThe estimated true incidence rates of pediatric melanoma from our population‐based study in Olmsted County, Minnesota, appear stable. This finding is in contrast to our prior research showing rapidly increasing incidence rates of melanoma in young and middle‐aged adults from the same population.
Distal Biceps Tendon Ruptures
Kelly, Mick P., Perkinson, Scott, Ablove, Robert H., Tueting, Jonathan L. , Perkinson, Scott G

The American Journal of Sports Medicine | June 10, 2015 | Volume: 43 | Issue: 8 | Pages: 2012-2017

10.1177/0363546515587738 | PMID 26063401 Get It

Background: The incidence of distal biceps tendon ruptures was studied more than 10 years ago in a small patient cohort. Recent diagnostic advancements have improved the ability to detect this rare injury. Hypothesis: The incidence of distal biceps tendon ruptures will be significantly greater than previously reported. Study Design: Descriptive epidemiologic study. Methods: A query of the PearlDiver Technologies national database containing public and private insurance patients was used to estimate the national incidence of distal biceps tendon ruptures in the United States. A retrospective chart review of our local population identified demographic groups and risk factors that increased likelihood of injury. Results: The estimated national incidence of distal biceps tendon rupture was 2.55 per 100,000 patient-years. The local incidence was 5.35 per 100,000 patient-years. The mean and median ages of patients in our regional cohort were 46.3 and 46 years, respectively. Males composed the majority of the injured population (national 95%, regional 96%). Smoking and elevated body mass index were found to be associated with increased likelihood of injury, while diabetes mellitus showed no association. Conclusion: The incidence of distal biceps tendon ruptures in this study was higher than previously reported.
Pediatric Lichen Planopilaris: Clinicopathologic Study of Four New Cases and a Review of the Literature
Christensen, Kevin, Lehman, Julia S. , Tollefson, Megha M. , Christensen, Kevin N, Lehman, Julia S

Pediatric Dermatology | June 10, 2015 | Volume: 32 | Issue: 5 | Pages: 621-627

10.1111/pde.12624 | PMID 26058419 Get It

Abstract Lichen planopilaris ( LPP ) is a rare form of cicatricial alopecia that has occasionally been reported in children. Because of the limited number of patients reported, little information is available about demographic characteristics, clinical presentation, or treatment options for these patients. A retrospective chart review of LPP cases in patients under 18 years of age from 1976 to 2013 was performed to further define clinicopathologic features of pediatric LPP . Four pediatric LPP patients ages 13 to 16 years were identified (three male, one female). One patient had scalp pruritus and one had other cutaneous findings of lichen planus ( LP ). Perifollicular scale and scarring were the most common physical examination findings, although changes mimicking those of alopecia areata were observed. Three patients were treated with topical or intralesional steroids. One patient was treated with minocycline. Histopathologic findings included perifollicular interface and perifollicular fibrosis in all cases. There was focal interfollicular interface in two cases and mild dermal mucin in one case. LPP is exceedingly rare in children. It may be misdiagnosed as alopecia areata in children because of the lack of symptoms and other features of LP . There should be a high index of suspicion for LPP in children with alopecia that is unresponsive to standard treatment or who have findings that are atypical for more common childhood alopecias.
Changes in written sign‐out composition across hospitalization
Miller, Donna , Schapira, Marilyn M. , Visotcky, Alexis, Laud, Purushottam W. , Arora, Vineet M. , Kordus, Andrew, Whittle, Jeff , Singh, Siddhartha , Fletcher, Kathlyn E. , Miller, Donna M, Miller, Donna M

Journal of Hospital Medicine | June 10, 2015 | Volume: 10 | Issue: 8 | Pages: 534-536

10.1002/jhm.2390 | PMID 26061434 Get It

BACKGROUNDInaccurate or incomplete information in the written portion of the patient handoff, or sign‐out, may be associated with adverse events in hospitalized patients. Little is known about what information providers actually include in written sign‐out documents and how sign‐outs change over time.OBJECTIVES(1) Provide a descriptive analysis of initial and subsequent hospital day‐written sign‐out content, and (2) evaluate the relationship between team workload and sign‐out composition.DESIGNRetrospective review of sign‐out documents from a larger observational study of general medicine patients admitted to housestaff and hospitalist teams at 3 hospitals.MAIN MEASURESThe presence of 13 components of a high‐quality sign‐out. We performed descriptive analyses and compared initial and subsequent day sign‐outs for content.KEY RESULTSWe reviewed 200 patient hospitalizations (200 initial handoffs, 580 subsequent day handoffs). Initial sign‐out entries contained a mean of 7.54 (standard deviation: 2.27) key sign‐out components. Subsequent day sign‐outs contained a higher percentage of certain key elements but had more vague language. The number of elements present in the sign‐out was reduced as patient census increased (r = −0.295, P < 0.01).CONCLUSIONSSign‐out composition changes over time, and is associated with workload. Future interventions to improve quality should take these factors into consideration. Journal of Hospital Medicine 2015;10:534–536. © 2015 Society of Hospital Medicine.
Retrospective Comparison of Posaconazole Levels in Patients Taking the Delayed-Release Tablet versus the Oral Suspension
Durani, Urshila , Tosh, Pritish K. , Barreto, Jason N. , Estes, Lynn L., Jannetto, Paul J. , Tande, Aaron J. , Tande, Aaron , Durani, Urshila

Antimicrobial Agents and Chemotherapy | June 10, 2015 | Volume: 59 | Issue: 8 | Pages: 4914-4918

10.1128/aac.00496-15 | PMID 26055378 Get It

ABSTRACT While posaconazole prophylaxis decreases the risk of invasive fungal infection compared to fluconazole, low bioavailability of the oral-suspension formulation limits its efficacy. A new delayed-release tablet formulation demonstrated an improved pharmacokinetic profile in healthy volunteers. However, serum levels for the two formulations have not been compared in clinical practice. This study compared achievement of therapeutic posaconazole levels in patients taking the delayed-release tablet to those taking the oral suspension. This retrospective cohort study included 93 patients initiated on posaconazole between 2012 and 2014 and had at least one serum posaconazole level measured. The primary measure was the proportion of patients achieving an initial therapeutic level (>700 ng/ml). An initial therapeutic posaconazole level was seen in 29 of 32 (91%) patients receiving tablets and 37 of 61 (61%) patients receiving suspension ( P = 0.003). Among patients with a steady-state level measured 5 to 14 days after initiation, a therapeutic level was observed in 18 of 20 (90%) patients receiving tablets and 25 of 43 (58%) patients receiving suspension ( P = 0.01). In these patients, the median posaconazole level of the tablet cohort (1655 ng/ml) was twice that of the suspension cohort (798 ng/ml) ( P = 0.004). In this cohort study, the improved bioavailability of delayed-release posaconazole tablets translates into a significantly higher proportion of patients achieving therapeutic serum levels than in the cohort receiving the oral suspension. The results of this study strongly support the use of delayed-release tablets over suspension in patients at risk for invasive fungal infection.
Does emotional intelligence change during medical school gross anatomy course? Correlations with students’ performance and team cohesion
Holman, Michelle A., Porter, Samuel G. , Pawlina, Wojciech, Lachman, Nirusha , Juskewitch, Justin E.

Anatomical Sciences Education | June 10, 2015 | Volume: 9 | Issue: 2 | Pages: 143-149

10.1002/ase.1541 | PMID 26062161 Get It

Emotional intelligence (EI) has been associated with increased academic achievement, but its impact on medical education is relatively unexplored. This study sought to evaluate change in EI, performance outcomes, and team cohesion within a team‐based medical school anatomy course. Forty‐two medical students completed a pre‐course and post‐course Schutte Self‐Report Emotional Intelligence Test (SSEIT). Individual EI scores were then compared with composite course performance grade and team cohesion survey results. Mean pre‐course EI score was 140.3 out of a possible 160. During the course, mean individual EI scores did not change significantly (P = 0.17) and no correlation between EI scores and academic performance was noted (P = 0.31). In addition, EI did not correlate with team cohesion (P = 0.16). While business has found significant utility for EI in increasing performance and productivity, its role in medical education is still uncertain. Anat Sci Educ 9: 143–149. © 2015 American Association of Anatomists.
Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N06
Barry, William T., Moreno‐Aspitia, Alvaro , Lyss, Alan P., Cirrincione, Constance, Leung, Eleanor H., Toppmeyer, Deborah , Perez, Edith A. , Hudis, Clifford A. , Leung, Eleanor, Mayer, Erica L. , Naughton, Michael, Carey, Lisa A. , Hudis, Clifford, Rugo, Hope S. , Naughton, Michael J. , Winer, Eric P.

Journal of Clinical Oncology | June 10, 2015 | Volume: 33 | Issue: 21 | Pages: 2361-2369

10.1200/jco.2014.59.5298 | PMID 26056183 Get It

PurposeWe compared nab-paclitaxel or ixabepilone once per week to paclitaxel with bevacizumab as first-line therapy for patients with advanced breast cancer (BC) to evaluate progression-free survival (PFS) for nab-paclitaxel or ixabepilone versus paclitaxel.Patients and MethodsEligible patients were age ≥ 18 years with chemotherapy-naive advanced BC. Patients were randomly assigned to bevacizumab with paclitaxel 90 mg/m2(arm A), nab-paclitaxel 150 mg/m2(arm B), or ixabepilone 16 mg/m2(arm C), once per week for 3 of 4 weeks. Planned enrollment was 900 patients, which would give 88% power to detect a hazard ratio of 0.73.ResultsIn all, 799 patients were enrolled, and 783 received treatment (97% received bevacizumab). Arm C was closed for futility at the first interim analysis (n = 241), and arm A (n = 267) and arm B (n = 275) were closed for futility at the second interim analysis. Median PFS for paclitaxel was 11 months, ixabepilone was inferior to paclitaxel (PFS, 7.4 months; hazard ratio, 1.59; 95% CI, 1.31 to 1.93; P < .001), and nab-paclitaxel was not superior to paclitaxel (PFS, 9.3 months; hazard ratio, 1.20; 95% CI, 1.00 to 1.45; P = .054). Results were concordant with overall survival; time to treatment failure was significantly shorter in both experimental arms v paclitaxel. Hematologic and nonhematologic toxicity, including peripheral neuropathy, was increased with nab-paclitaxel, with more frequent and earlier dose reductions.ConclusionIn patients with chemotherapy-naive advanced BC, ixabepilone once per week was inferior to paclitaxel, and nab-paclitaxel was not superior with a trend toward inferiority. Toxicity was increased in the experimental arms, particularly for nab-paclitaxel. Paclitaxel once per week remains the preferred palliative chemotherapy in this setting.
Association Between Atrial Fibrillation Symptoms, Quality of Life, and Patient Outcomes
Simon, DaJuanicia N., Go, Alan S. , Spertus, John A. , Fonarow, Gregg C. , Kowey, Peter R. , Mahaffey, Kenneth W. , Thomas, Laine , Chang, Paul, Piccini, Jonathan P. , Freeman, James V. , Spertus, John, Thomas, Laine E, Gersh, Bernard J. , Hylek, Elaine M. , Peterson, Eric D. , Spertus, John A

Circulation: Cardiovascular Quality and Outcomes | June 10, 2015 | Volume: 8 | Issue: 4 | Pages: 393-402

10.1161/circoutcomes.114.001303 | PMID 26058720 Get It

Background— Instruments to assess symptom burden and quality of life among patients with atrial fibrillation (AF) have not been well evaluated in community practice or associated with patient outcomes. Methods and Results— Using data from 10 087 AF patients in the Outcomes Registry for Better Informed Treatment of AF (ORBIT-AF), symptom severity was evaluated using the European Heart Rhythm Association (EHRA) classification system, and quality of life was assessed using the Atrial Fibrillation Effect on Quality-of-Life (AFEQT) questionnaire. The association between AF-related symptoms, quality of life, and outcomes was assessed using Cox regression. The majority of AF patients (61.8%) were symptomatic (EHRA >2) and 16.5% had severe or disabling symptoms (EHRA 3–4). EHRA symptom class was well correlated with the AFEQT score (Spearman correlation coefficient −0.39). Over 1.8 years of follow-up, AF symptoms were associated with a higher risk of hospitalization (adjusted hazard ratio for EHRA ≥2 versus EHRA 1 1.23, 95% confidence interval, 1.15–1.31) and a borderline higher risk of major bleeding. Lower quality of life was associated with a higher risk of hospitalization (adjusted hazard ratio for lowest quartile of AFEQT versus highest 1.49, 95% confidence interval, 1.2–1.84), but not other major adverse events, including death. Conclusions— In a community-based study, most patients with AF were symptomatic and had impaired quality of life. Quality of life measured by the AFEQT correlated closely with symptom severity measured by the EHRA class. AF symptoms and lower quality of life were associated with higher risk of hospitalization but not mortality during follow-up.